Furthermore, any generic being manufactured in India or...

Furthermore, any generic being manufactured in India or elsewhere will be able to be valued according to any standard accounting valuation tool. Therefore, like any other widget manufacturer somebody somewhere knows something before someone else. Most likely in India. Which makes it impossible for a retail shareholder to gain a competitive advantage over market insiders. Especially if they are India resident.

It is my belief that this is not where a retail investor should be operating at this stage of the business cycle.

Rather, much like a large part of a companies valuation can come from accounting of intangibles like a brand or logo or trademark representing such, a biotech's valuation will come from its patent suite and freedom to operate granted from this.

Once commercialized sufficiently, these patents will be granted a accounting value which by any stretch should be substantial relative to current market caps and what its natural customer, pharmaceutical companies, are willing to pay.

Thus, if one wishes to look for undervalued cancer biotechs one should be picking over the m-cabs and immunos with novel innovative patent estates that are no later than PII.